

Total Dietary Fat Intake, Fat Quality, and Health Outcomes: A Scoping Review of Systematic Reviews of Prospective Studies

Lukas Schwingshackl^a Jasmin Zähringer^a Jessica Beyerbach^a
Sarah W. Werner^a Helmut Heseke^b Berthold Koletzko^c Joerg J. Meerpohl^{a, d}

^aInstitute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ^bDepartment of Sports and Health, Paderborn University, Paderborn, Germany; ^cDivision of Metabolic and Nutritional Medicine, Department Paediatrics, Dr. von Hauner Children's Hospital, University of Munich Medical Center, LMU – Ludwig-Maximilians-Universität Munich, Munich, Germany; ^dCochrane Germany, Cochrane Germany Foundation, Freiburg, Germany

Keywords

Scoping review · Dietary fat · Fat quality · Systematic reviews · Health outcomes

Abstract

Introduction: We conducted a scoping review of systematic reviews (SRs) on dietary fat intake and health outcomes in human adults within the context of a position paper by the “International Union of Nutritional Sciences Task force on Dietary Fat Quality” tasked to summarize the available evidence and provide dietary recommendations. **Methods:** We systematically searched several databases for relevant SRs of randomized controlled trials (RCTs) and/or prospective cohort studies published between 2015 and 2019 assessing the association between dietary fat and health outcomes. **Results:** Fifty-nine SRs were included. The findings from SRs of prospective cohort studies, which frequently compare the highest versus lowest intake categories, found mainly no association of total fat, monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), and saturated fatty acid (SFA) with risk of chronic diseases. SRs of RCTs applying substitution analyses indicate that SFA replacement with PUFA and/or MUFA improves blood lipids and glycemic control,

with the effect of PUFA being more pronounced. A higher intake of total trans-fatty acid (TFA), but not ruminant TFA, was probably associated with an increased risk of mortality and cardiovascular disease based on existing SRs. **Conclusion:** Overall, the available published evidence deems it reasonable to recommend replacement of SFA with MUFA and PUFA and avoidance of consumption of industrial TFA.

© 2021 S. Karger AG, Basel

Introduction

Worldwide, noncommunicable diseases, such as cardiovascular disease (CVD), cancer, and type 2 diabetes (T2D), account for over 70% of total deaths [1]. According to the Global Burden of Disease Study, suboptimal diet is the leading risk factor for about 50% of disabilities from CVDs [2].

In the past, recommendations to limit dietary fat intake to prevent chronic diseases were issued by many organizations and advisory bodies. For example, in 1980, the Dietary Guidelines for Americans (DGA) called for a limitation of dietary fat intake to <30% of total energy intake (TEI) [3] and changed to recommend “choose a diet

that is low in saturated fat and cholesterol and moderate in total fat” to in 2000 and eliminated in 2015. The earlier recommendations were largely based on ecological studies and trials evaluating single intermediate disease markers, for example, serum total cholesterol (TC) levels. Compared to decades ago, the field of nutritional science now benefits from a richer repertoire of methodological approaches to assess diet-disease relationships, notably large, long-term prospective cohort studies and well-controlled randomized controlled trials (RCTs) which assess multiple clinical end points.

Systematic reviews (SRs) and meta-analyses (MAs) nowadays constitute the preferred methodology to summarize the body of available evidence for the development of dietary recommendations. They offer the possibility to synthesize a wealth of data, to explain inconsistencies or inconclusiveness, and to generate new knowledge by supporting valid and reliable conclusions based on scientific evidence. In the DGA 2015–2020, dietary recommendations were based on newly conducted SRs, existing SRs, and reports by federal agencies or leading scientific organizations [4]. However, the DGA have also been criticized for failing to take into account all available relevant scientific evidence (by omitting, e.g., available evidence on saturated fatty acid [SFA]) [5].

The scope of our review is to identify, describe, and summarize comprehensively the currently available evidence for total dietary fat or fat quality and risk of chronic diseases through collation and analysis of SRs of RCTs and prospective cohort studies published between 2015 and 2019. The rationale for focusing on this time frame was the large number of SRs of RCTs and cohort studies published between 2015 and 2019, which have not been subject to a comparable scoping review (ScR). Our ScR is the first in this research field and will serve as a basis for a position paper by the “International Union of Nutritional Sciences (IUNS) Task force on Dietary Fat Quality” that was tasked to summarize the available evidence and provide dietary recommendations.

Methods

We conducted this ScR in accordance with the methodology of the Joanna Briggs Institute’s Reviewers’ Manual [6]. For reporting, we followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for ScRs, the PRISMA-ScR statement [7].

Search Strategy

The databases MEDLINE (via Ovid), the Cochrane Database of Systematic Reviews, and Epistemonikos were searched from January 1, 2015 to December 31, 2019 for relevant articles (search con-

ducted: February 19, 2020). The search strategy was developed and adapted for each database accordingly, and there was no restriction by language. The MEDLINE (Ovid), Cochrane Library, and Epistemonikos search strategy are presented in the online suppl. Appendix 1; see www.karger.com/doi/10.1159/000515058 for all online suppl. material. Moreover, forward citation tracking and reference checking from included documents were performed.

Selection of Studies

Inclusion Criteria

SRs fulfilling the following criteria were included in the ScR: (i) SRs of RCTs or prospective cohort studies, including nested case-control studies and case-cohort studies, involving adults as study participants published within the last 5 years (2015–2019). (ii) SRs focusing on interventions of or exposure to dietary fat (total fat) and/or fat quality, that is, SFA, monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), trans-fatty acid (TFA) including industrial versus ruminant TFA, omega-6 (linoleic acid [LA] and conjugated linoleic acid [CLA]), omega-3 fatty acids (FAs) including eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA); and α -linolenic acid (ALA), and dietary cholesterol. (iii) SRs reporting any of the following outcomes: all-cause mortality (ACM); chronic disease outcomes, such as CVD, coronary heart disease (CHD), and stroke; cancer, for example, breast, colorectal, gastric, endometrial, ovarian, pancreatic, and prostate cancer; T2D; hypertension; obesity; and intermediate disease markers, such as high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triacylglycerols (TG), systolic blood pressure, and diastolic blood pressure; glyce-mic control parameters, such as fasting glucose and glycosylated hemoglobin (HbA1c); C-reactive protein (CRP); and anthropometric outcomes, such as body weight (BW), fat mass, and waist circumference.

Exclusion Criteria

SRs that met any of the following criteria were excluded: (i) inclusion of solely critically ill and hospitalized patients, patients undergoing bariatric surgery, patients with eating disorders, or patients with T2D; inclusion of more than one-third of the patients/population suffering from CVD or cancer (due to the primary prevention focus of the IUNS Task force on Dietary Fat Quality position paper). (ii) Interventions/exposure with dietary supplements (for more than one-third of the population/patients); interventions/exposure including solely oils (e.g., olive oil) or solid fats (e.g., butter); or including circulating FAs as exposure. (iii) SRs of nonrandomized intervention trials, case-control, or cross-sectional studies.

Selection Process of Sources of Evidence

First, title and abstract screening was performed by 1 reviewer (J.Z.). Only clearly irrelevant references were excluded at this stage. Second, for all potentially relevant references, full-text publications were obtained and checked for final inclusion by 2 reviewers (J.Z. and L.S.) independently. Uncertainties were resolved through discussion with a third author (J.J.M.).

Data Extraction

For included SRs, 2 reviewers (J.B. and S.W.) extracted the study characteristics, and another reviewer cross-checked all extracted data (J.B., S.W., and L.S.). The following data were extract-




Fig. 1. Flow diagram showing study selection process.

ed: author, year of publication, aim of systematic review, design of included studies, number of included studies (for the corresponding outcomes), number of participants (for the corresponding outcome), description of participants/population, description of intervention/exposure, comparison parameter (e.g., high vs. low intake category), outcomes, direction of effect, certainty of evidence, search date of systematic review, and databases searched.

Data Categorization and Presentation

Besides a descriptive summary of the current research landscape on the effects and association of total dietary fat intake and fat quality with health outcomes, we visually displayed our results using a bubble plot. Bubble charts are used to highlight the main relationship between total dietary fat intake and fat quality by charting the intervention/exposure, the health outcomes assessed, and the study design.

Results

Out of 5,331 records identified by the literature searches, 257 records were assessed as full texts (Fig. 1; online suppl. Appendix 2). We excluded articles that failed to meet the required study design (RCTs and prospective cohort studies), which did not examine the interventions/

exposures of interest, or that assessed outcomes or populations outside of the scope of this work. Finally, 59 SRs on total dietary fat intake and fat quality published in the last 5 years were included in the ScR [8–66].

Fifteen SRs included exclusively RCTs [18–20, 32, 34, 35, 45, 49–51, 53, 57, 60, 61, 63], 41 SRs solely prospective cohort studies [8, 10–14, 16, 17, 21–31, 33, 37–44, 46–48, 52, 54–56, 58, 59, 62, 64–66], and 3 SRs both study types [9, 15, 36]. The number of studies and participants for the outcomes in a SR varied between 1 [14, 31] and 99 [32] for studies and between 417 [51] and 1,786,537 [23] for participants. The types of participants varied across included SRs: whereas SRs of RCTs included mainly healthy and overweight/obese adults, SRs of prospective observational studies included mainly participants from the general population, whose characteristics were less well described. Types of interventions in the included SRs of RCTs encompassed low-fat diets (LFDs), diets rich in MUFA, PUFA, LA or dietary cholesterol, and diets replacing SFA by PUFA or MUFA. Types of total dietary fat intake and fat quality in the included SRs of prospective observational studies covered exposure intake of total fat, MUFA, PUFA, SFA, TFA (industrial, ruminant), ome-

	Total Fat	Low - Fat *	MUFA	PUFA	SFA	TFA	TFA (industrial)	TFA (ruminant)	LA	n-3 PUFA	ALA	EPA/DHA	CLA	Dietary cholesterol
All-cause mortality		↓		●	○	↑	○	○				○↓↓		
Breast cancer	↑		○	○	○	○			○				○	○
Cancer		●												
Cardiovascular disease	○	●	○	●	○	↑						↓		
Colorectal cancer	○		○	○	○					○	○	↓		
Coronary heart disease	○				○	↑	↑	○		○	○↓	↓		
Endometrial cancer	↓	○	○↓	○	○	○			○					○
Gastric cancer	○		○	↓	↑									
Hypertension										○				
Lung cancer														○
Non-Hodgkin Lymphoma	↑													
Ovarian cancer	○	○	○	○	○	○								
Pancreatic cancer			○	○	○									○
Prostate cancer	○		○	○	○						○	○	○	
Skin cancer	○		○	○	○									
Stroke			○		↓	↓	○					↓	↓	○
Type 2 diabetes					○	○		↓		○		↑		

Fig. 2. Bubble plot showing the associations/effects between dietary fat/fat quality and patient relevant outcomes. Number of circles and arrows represent the number of studies. *As part of a weight-reducing diet vs. a control (nonweight reducing) diet. ALA, α -linolenic acid; CLA, conjugated linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acids SFA, saturated fatty acid; TFA, trans fatty acid; ACM, all-cause mortality; CHD, coronary heart disease; CVD, cardiovascu-

lar disease; T2D, type 2 diabetes; SRs, systematic reviews; RCTs, randomized controlled trials; CI, confidence interval. ↑, SRs of prospective cohort studies: a positive association was shown (95% CI does not cross the null effect); ○, SRs of prospective cohort studies: there was no (significant) association; ↓, SRs of prospective cohort studies: an inverse association was shown (95% CI does not cross the null effect); ●, SRs of RCTs: no (significant) effect (SRs of RCTs); ↓, SRs of RCTs: a decreasing effect was shown (95% CI does not cross the null effect).

ga-6 (LA and CLA), omega-3 FA (EPA, DHA, and ALA), and dietary cholesterol. The majority of the included SRs conducted MAs comparing the highest versus lowest intake category.

Online suppl. Table 1 shows the general and specific characteristics of the included SRs. Associations and effects between health outcomes by study design and type of total dietary fat intake and fat quality are shown in Figures 2 and 3.

Health Outcomes Assessed in the Included Studies

In the SRs of RCTs, the investigated health outcomes included ACM, CVD, cancer, blood lipids, blood pressure, glycemic control, CRP, and anthropometric outcomes such as BW, fat mass, and waist circumference (Fig. 2, 3) [9, 15, 18–20, 32, 34–36, 45, 49–51, 53, 57, 60, 61, 63]. In the SRs of prospective observational studies, the investigated health outcomes included ACM, CVD (CHD and stroke), T2D, hypertension, and different types of cancer (breast, colorectal, endometrial, gastric,

	Low-Fat*	MUFA	PUFA	SFA replaced by PUFA	SFA replaced by MUFA	LA	Dietary cholesterol
Body weight	↓●↓↑↑↓		↑				
C-reactive protein	●					●	
Diastolic blood pressure	↑●	●					
Fasting glucose	●		●	↓	●		
Glycosylated hemoglobin				↓	↓		
High-density lipoprotein cholesterol	↓●↓↓↓		●	↓	●		↑
Low-density lipoprotein cholesterol	↓↓↓↓↓		●	↓	↓		↑
Systolic blood pressure	●●●	●					
Total cholesterol	↓●↓↓↓		●	↓	↓		↑
Triacylglycerols	↑●↑↑↑		●	↓	↓		●
Waist circumference	↓						

Fig. 3. Bubble plot showing the effects between dietary fat/fat quality and intermediate disease outcomes. Number of circles and arrows represent the number of studies. *Compared to lower carbohydrate/higher fat (presumably higher in SFA) diets. LA: linoleic acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; SRs, systematic reviews; RCTs, randomized controlled trials; CI, confidence interval; BW, body weight; CRP, C-reactive protein; FG, fasting glucose; DBP, dia-

stolic blood pressure; SBP, systolic blood pressure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triacylglycerol; WC, waist circumference. ●, SRs of RCTs: no (significant) effect (SRs of RCTs); ↓, SRs of RCTs: a decreasing effect was shown (95% CI does not cross null effect); ↑, SRs of RCTs: a increasing effect was shown (95% CI does not cross null effect).

lung, ovarian, pancreatic, prostate, skin cancer, and non-Hodgkin lymphoma) [8–17, 21–31, 33, 36–44, 46–48, 52, 54–56, 58, 59, 62, 64–66].

Effects and Associations of Total Fatty Acids

In SRs of RCTs, MAs found that LFD (<30% dietary fat of TEI; and higher in carbohydrates) improves LDL-C and TC compared to lower carbohydrate/higher fat (presumably higher in SFA) diets, whereas a lower carbohydrate/higher fat diet performed better for HDL-C and TG [15, 19, 34, 57, 60]. In this regard in a SR of RCTs was shown that isocaloric replacement of carbohydrates by SFA raises TC, LDL-C, and HDL-C and reduces TG, whereas replacement of carbohydrates by MUFA and

PUFA reduces TC, LDC, and TG and increases HDL-C [35]. The findings of LFD on anthropometric outcomes were inconsistent. One SR favored a LFD [15], whereas other SRs observed no significant differences [20, 57] or favored a lower carbohydrate/higher fat diet [19, 34]. One SR of RCTs found that weight reducing diets, usually low in fat and SFA, with or without exercise, may reduce premature ACM, but no effect on cancer and CVD risk in adults with obesity was observed [49] (Fig. 2, 3). In a majority of SRs of prospective observational studies, total fat intake was not associated with increased risk of ACM, CVD mortality, and several cancer types [14, 16, 17, 24, 27, 37, 39, 44, 46, 55, 62, 64] (Fig. 2).

Table 1. Available GRADE certainty of evidence ratings for total fat and fatty acids according to the investigated patient relevant outcomes and intermediate disease markers

	Total fat	MUFA	PUFA	SFA	Total TFA	TFA (industrial)	TFA (ruminant)
<i>Patient relevant outcomes</i>							
ACM	↓ high [†]	na	na	○ very low	↑ low	○ very low	○ very low
CVD (incidence/mortality)	○ high [†]	na	na	○ very low	na	na	na
CHD	na	na	na	na	↑ moderate	↑ very low	○ very low
Stroke	na	na	na	na	○ very low	na	na
T2D	na	na	na	○ very low	○ very low	na	↓ very low
Cancer (incidence/mortality)	○ very low [†]	na	na	na	na	na	na
<i>Intermediate disease markers</i>							
Blood lipids	na	↓ high [§]	↓ high [§]	na	na	na	na
BP	na	○ moderate	na	na	na	na	na
BW	↓ high [‡]	na	na	na	na	na	na
FG	na	na	○ moderate	na	na	na	na

na, not available; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; TFA, trans-fatty acids; ACM, all-cause mortality; CVD, cardiovascular disease; CHD, coronary heart disease; T2D, type 2 diabetes; BW, body weight; BP, blood pressure; FG, fasting glucose; CI, confidence interval. [†] Weight loss interventions (usually low-fat diet and low SFA intake). [‡] Low-fat diet. [§] SFA replacement by MUFA and PUFA. [†] A positive association was shown (95% CI does not cross the null effect); [↓] A inverse association was shown (95% CI does not cross the null effect); [○] there was no (significant) association.

Effects and Associations of MUFA

In SRs of RCTs, a higher MUFA (median: 20% of TEI) intake mainly substituting carbohydrates had no effect on blood pressure [61] (Fig. 3). In SRs of prospective observational studies, a higher overall MUFA intake was not associated with risk of CVD (and stroke) and several types of cancer [14, 16, 22, 24, 25, 27, 29, 37, 39, 55, 62, 64] (Fig. 2).

Effects and Associations of PUFA

In SRs of RCTs, a higher PUFA ($\geq 6\%$ of TEI) intake mainly substituting SFA and carbohydrates had little or no effect on ACM, CVD, blood lipids, and fasting glucose but leads to a slight increase in BW (0.76 kg) [53, 63] (Fig. 3). In SRs of prospective observational studies, a higher overall PUFA intake was not associated with risk of CVD, hypertension, and several cancer types [14, 16, 22, 24, 25, 27, 37–39, 55, 62, 64] (Fig. 2).

Effects and Associations of SFA

An isocaloric substitution (1 or 5% of TEI) of SFA with PUFA and MUFA improved TC, LDL-C, TG, and biomarkers of glycemic control [32, 35] (Fig. 3). Isocaloric replacement of carbohydrates with lauric acid, myristic acid, and palmitic acid raises TC, LDL-C, and HDL-C, and reduces TG [35]. Isocaloric replacement of carbohydrates with stearic acid did not affect blood lipids [35]. In a majority of SRs of prospective observational studies, a

higher SFA intake was not associated with risk of ACM, CVD, T2D, and several cancer types [12, 14, 16, 22–25, 27, 36, 37, 39, 46, 62, 64]; however, it was inversely associated with risk of stroke [30, 65] (Fig. 2).

Effects and Associations of TFA

In SRs of prospective observational studies, a higher total TFA intake was associated with increased risk of ACM, CVD, and CHD but not with T2D, stroke, breast, and ovarian cancer [12, 37, 59, 64]. Higher industrial TFA intake was probably associated with CHD risk, whereas higher ruminant TFA intake showed no association with mortality and CVD and an inverse association with risk of T2D [12] (Fig. 2).

Effects and Associations of Omega-6 Fatty Acids

SRs of prospective cohort studies found no association between LA intake and risk of endometrial and breast cancer [39, 40] (Fig. 2). No effects were observed for CRP [50] (Fig. 3). We found no associations between risk for breast cancer and CLA intake [47, 59] (Fig. 2).

Effects and Associations of Omega-3 Fatty Acids

In SRs of prospective cohort studies, a higher intake of n-3 PUFA was not associated with CHD, hypertension, T2D, and colorectal cancer [38, 43, 48, 66]. Higher EPA/DHA intake was mainly inversely associated with risk of ACM, CVD, CHD, stroke, and colorectal cancer [11, 28,

41, 42, 48, 52, 55, 66] but had no effect on the risk for prostate cancer [8, 13] and was positively associated with T2D [43] (Fig. 2). We found no associations between risk for cancer and ALA intake [13, 55]. Higher ALA intake was inversely associated with risk of CHD [58] in one SR, whereas another SR observed no association [42].

Effects and Associations of Dietary Cholesterol

In SRs of RCTs, a higher dietary cholesterol intake was associated with raised blood lipid levels [9]. In SRs of prospective cohort studies, no association between higher dietary cholesterol intake and stroke or cancer risk was observed [10, 21, 31, 33, 54, 56].

Certainty of Evidence Ratings

Only 7 out of 59 SRs graded the certainty of the evidence [12, 15, 35, 42, 49, 61, 63] (Table 1). The beneficial effect of replacing SFA through MUFA and PUFA on blood lipid levels was rated as high certainty of evidence. The positive association between total TFA intake and CHD risk was rated as moderate certainty of evidence, whereas the positive association between total TFA intake and ACM was rated as low certainty of evidence.

Discussion

Summary of Findings

This ScR is the first to summarize the available SRs of RCTs and prospective observational studies on total dietary fat intake, fat quality, and health outcomes in human adults. Overall, 59 SRs published between 2015 and 2019 fulfilling our criteria were identified. The main SRs identified in our ScR found no evidence for an association of total fat intake with risk of ACM, CVD, and cancer. The findings from the included SRs of prospective cohort studies, which often compare the highest versus lowest intake categories, mainly found no association between MUFA, PUFA, and SFA intake and risk of chronic disease. However, SRs of RCTs applying substitution analyses indicate that SFA replacement with PUFA and/or MUFA improves blood lipids (high certainty of evidence) and glycemic control, with a more pronounced effect with PUFA replacement. Considering the types of SFA, isocaloric replacement of carbohydrates with lauric acid, myristic acid, and palmitic acid raises TC, LDL-C, and HDL-C and reduces TG, whereas stearic acid has little effect on blood lipids. Of note, the carbohydrate quality should be considered as well. Findings from cohort studies and RCTs showed that higher intakes of dietary fiber

and whole grains indicate that the inverse relationships with several noncommunicable diseases could be causal [67, 68], whereas higher intakes of added sugar and refined starches have detrimental health effects [69–71].

A higher intake of total TFA was probably associated with an increased risk of ACM, CVD, and CHD. Higher industrial TFA intake was associated with CHD risk, whereas ruminant TFA intake showed no association with mortality and CVD and an inverse association with risk of T2D. In the past, evidence from RCTs has shown stronger detrimental effects of TFA on blood lipids than SFA [72]. A higher intake of EPA/DHA was inversely associated with risk of ACM, CVD, and stroke across SRs of prospective cohort studies. Unfortunately, only a few identified SRs graded the certainty of evidence. Moderate certainty of evidence suggests that a higher total TFA intake was associated with increased risk of CHD. High certainty of evidence suggests that SFA replacement by MUFA and PUFA improves blood lipid levels.

A Cochrane review that was excluded from our ScR due to the high number of secondary prevention trials included provides moderate certainty of evidence suggesting that a reduction of SFA and its replacement with PUFA reduces the risk of CVD [73]. Furthermore, the National Health and Nutrition Examination Survey showed that an isocaloric substitution (10% TEI) of SFA with PUFA or MUFA was inversely associated with overall mortality [74]. On the contrary, SFA intake was inversely associated with the risk of stroke in Asian populations [65, 75].

Global Fat Intake and Current Dietary Fat Recommendations

A systematic assessment of the Global Burden of Diseases Nutrition and Chronic Diseases Expert Group evaluating the consumption of dietary fat based on over 300 dietary surveys shows that the mean PUFA intake is approximately 6% and the mean SFA intake is approximately 10% worldwide [76]. In the European Prospective Investigation into Cancer and Nutrition cohort study, the mean total fat intake was $\geq 35\%$ of TEI, among which $\geq 14\%$ accounted for SFA, 10–13% accounted for MUFA, and 4–8% accounted for PUFA intake [77]. These data show that current intake of dietary fat exceeds dietary recommendations. Our ScR of 20 dietary guidelines shows that most of them recommend total fat intakes of 30– $\leq 35\%$ of TEI [78]. Most guideline organizations specified a quantitative range for SFA of between $\leq 7\%$ (for patients with metabolic disorders) and $\leq 11\%$ of TEI and further recommend replacement of SFA with MUFA and/or

PUFA [78]. Most organizations recommend complete avoidance of TFA or limit intake to $\leq 2\%$ of TEI [78]. Only a few organizations give quantitative recommendations for MUFA or PUFA, which range between 10 and 25% for MUFA and between 5 and 11% for PUFA of TEI.

Comparison with Findings from Systematic Reviews on Oils and Solid Fats

The WHO guideline drafts on SFA and TFA have been recently criticized for not providing a food-based translation of the recommendations [79]. Analyzing the effects of SFA-rich foods on health outcomes, a MA of 16 intervention studies has recently shown that coconut oil consumption results in higher LDL-C than nontropical vegetable oils [80], whereas an SR of prospective observational studies found a relatively small or no associations of butter with mortality, CVD, and T2D [81]. An SR including both RCTs and prospective cohort studies observed that the intake of olive oil, which is a rich source of plant MUFA, could be beneficial for the prevention and management of T2D. Moreover, high phenolic olive oil may improve some cardiovascular risk factors stronger than refined olive oil [82, 83]. Higher consumption of canola oil results in a modest decrease in BW, whereas no significant effect was observed on other adiposity measures [84].

Finally, a network meta-analysis of 54 RCTs showed that, compared to butter, oils rich in unsaturated FAs such as safflower, sunflower, rapeseed, flaxseed, corn, olive, or soybean oil were more effective in reducing LDL-C. The network meta-analysis findings align with existing evidence on the metabolic effects of fat and support current recommendations to replace SFA-rich foods with unsaturated oils [85].

Another SR summarized the data related to foods high in SFA and risk of mortality [86]. Pooled risk estimates showed that higher intakes of milk, cheese, yogurt, and butter were not associated with risk of mortality than lower intakes. However, higher intakes of meat and processed meat were associated with an increased risk of ACM.

Strengths and Limitations

This ScR has several strengths. First, the inclusion criteria and the search strategy planned for this ScR enabled a broad, yet in-depth, view on the topic by taking into account both SRs of RCTs and prospective cohort studies based on an extensive search of 3 databases. We included a variety of dietary fats, including total fat, MUFA, PUFA, SFA, TFA, omega-3 and omega-6 FAs, and several health outcomes such as ACM, CVD, T2D, cancer, blood lipids,

blood pressure, glycemic control, CRP, and anthropometric outcomes.

Limitations need to be considered as well. This review did not include studies focusing on dietary fat intake and health outcomes in vulnerable subgroups such as infant, children and adolescents, and pregnant and lactating women. A further limitation of our approach is its qualitative/nonquantitative findings. We did not evaluate the methodological quality of the identified SRs, and therefore, the methodological quality may vary substantially. Overall, the generalizability of our findings is limited because in our ScR: (i) SRs were only included if more than two-thirds of the included studies in an SR focused on dietary intake of fat rather than fat from dietary supplements and included less than one-third study participants with secondary prevention of CVD or T2D; (ii) SRs focusing on health outcomes such as metabolic syndrome, dementia, CKD, or respiratory diseases among others were omitted; (iii) we did not cover the full spectrum of possible dietary fat intake since we excluded SRs focusing on the consumption of omega-3 supplements, specific oils, and solid fat intake or other fatty foods. Several MAs of RCTs have shown either no effect or only very small benefits of omega-3 supplements on CVD risk [87, 88]. Focusing on foods rather than nutrients has been suggested recently also by Astrup and colleagues [89]. SR of prospective cohort studies has shown mainly no detrimental association between SFA-rich foods such as dairy or chocolate and risk of noncommunicable diseases [68, 90–95]. To improve the trustworthiness of such food-disease associations, rating the certainty of evidence [96, 97] and the use of novel statistical methods (e.g., substitution analyses or network MAs) is highly recommended [98, 99]; (iv) SR of prospective cohort studies frequently compared the highest versus lowest intake categories, whereas conducting dose-response (linear and nonlinear) MAs and substitution analyses would be more informative [100]. The SRs findings of RCTs also need to be interpreted with caution since not all primary studies were based on isocaloric substitution, and replacement with other dietary fats, carbohydrates, and/or protein might differ substantially between study arms.

Conclusion

SRs of prospective cohort studies mainly found little or no association of MUFA, PUFA, and SFA with risk of chronic disease but suggest to a positive association between higher intake of total TFA and an increased risk of ACM, CVD, and CHD but not ruminant TFA. Evidence

from RCTs has shown stronger detrimental effects of TFA on blood lipids than SFA. Substitution analyses indicate that SFA replacement with PUFA and/or MUFA improves blood lipids and glycemic control across bodies of evidence from RCTs. Overall, current recommendations to replace SFA with MUFA and PUFA and avoid the consumption of industrial TFA seems reasonable.

Acknowledgements

We are grateful to the members of the IUNS Task force on Dietary Fat Quality [Prof. Tom Brenna, Prof. Irina Kovalskys, Prof. Alice Lichtenstein, Prof. Ronald Mensink, Prof. Ladda Mo-Suwan, Prof. Marius Smuts, Prof. Shoichiro Tsugane, and Prof. Yang Yuexin] for their critical review of this article and insightful comments.

Statement of Ethics

Ethics Committee approval was not required since this paper is a systematic review, and no experimental procedure was performed in human beings.

References

- 1 Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390(10100):1151–210.
- 2 Afshin A, Sur PJ, Fay KA, Cornaby L, Ferrara G, Salama JS, et al. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2019;393(10184):1958–72.
- 3 U.S. Department of Health and Human Services. Nutrition and your Health. *Dietary Guidelines for Americans*. United States 1980. Available from: <https://health.gov/our-work/food-nutrition/previous-dietary-guidelines/1980>. Access Date: 2020 Feb 12.
- 4 U.S. Department of Health and Human Services and U.S. Department of Agriculture. *2015–2020 dietary guidelines for Americans*. 8th ed.; 2015 Dec. Available from: <http://health.gov/dietaryguidelines/2015/guidelines/>. Access Date: 2020 Feb 12.
- 5 Teicholz N. The scientific report guiding the US dietary guidelines: is it scientific? *BMJ*. 2015;351:h4962.
- 6 Peters MDJ, Godfrey C, McInerney P, Baldini Soares C, Khalil H, Parker D. Chapter 11: scoping reviews. In: Aromataris E, Munn Z, editors. *Joanna Briggs Institute reviewer's manual*. The Joanna Briggs Institute; 2017. Available from: <https://wiki.jbi.global/display/MANUAL>. Access Date: 2020 Oct 21.
- 7 Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med*. 2018 Oct 2;169(7):467–73.
- 8 Alexander DD, Bassett JK, Weed DL, Barrett EC, Watson H, Harris W. Meta-analysis of long-chain omega-3 polyunsaturated fatty acids (LComega-3PUFA) and prostate cancer. *Nutr Cancer*. 2015;67(4):543–54.
- 9 Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. *Am J Clin Nutr*. 2015 Aug; 102(2):276–94.
- 10 Chen X, Zhou T, Chen M. Meta analysis of the association of cholesterol with pancreatic carcinoma risk. *J Buon*. 2015 Jan–Feb;20(1):109–13.
- 11 Cheng P, Huang W, Bai S, Wu Y, Yu J, Zhu X, et al. BMI affects the relationship between long chain N-3 polyunsaturated fatty acid intake and stroke risk: a meta-analysis. *Sci Rep*. 2015 Sep 15;5:14161.
- 12 de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. *BMJ*. 2015 Aug 11;351:h3978.
- 13 Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. *J Epidemiol*. 2015;25(4):261–74.
- 14 Han J, Jiang Y, Liu X, Meng Q, Xi Q, Zhuang Q, et al. Dietary fat intake and risk of gastric cancer: a meta-analysis of observational studies. *PLoS One*. 2015;10(9):e0138580.
- 15 Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. *Cochrane Database Syst Rev*. 2015 Aug 7(8):Cd011834.
- 16 Hou R, Wu QJ, Gong TT, Jiang L. Dietary fat and fatty acid intake and epithelial ovarian cancer risk: evidence from epidemiological studies. *Oncotarget*. 2015 Dec 15;6(40): 43099–119.
- 17 Jiang L, Hou R, Gong TT, Wu QJ. Dietary fat intake and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. *Sci Rep*. 2015 Nov 16;5:16693.
- 18 Leslie MA, Cohen DJ, Liddle DM, Robinson LE, Ma DW. A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. *Lipids Health Dis*. 2015 Jun 6;14:53.
- 19 Sackner-Bernstein J, Kanter D, Kaul S. Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. a meta-analysis. *PLoS One*. 2015;10(10):e0139817.

Conflict of Interest Statement

L.S.: is a member of the GRADE working group; B.N.: is a member of the GRADE working group; J.J.M.: is a member of the WHO Nutrition Guidance Expert Advisory Group; Director, Freiburg GRADE Center. Other others declare that they have no conflict of interest to declare.

Funding Sources

International Union of Nutritional Sciences.

Author Contributions

L.S., J.Z., J.B., S.S.W., H.H., B.K., and J.J.M. designed the research. L.S., J.Z., and J.B. analyzed the data and wrote the first draft of the paper. L.S., J.Z., J.B., S.S.W., H.H., B.K., and J.J.M. interpreted the data, read the manuscript, and approved the final version. L.S. and J.J.M. are guarantors.

- 20 Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*. 2015 Dec;3(12):968–79.
- 21 Wang J, Wang WJ, Zhai L, Zhang DF. Association of cholesterol with risk of pancreatic cancer: a meta-analysis. *World J Gastroenterol*. 2015 Mar 28;21(12):3711–9.
- 22 Wu QJ, Gong TT, Wang YZ. Dietary fatty acids intake and endometrial cancer risk: a dose-response meta-analysis of epidemiological studies. *Oncotarget*. 2015 Nov 3;6(34):36081–97.
- 23 Xia H, Ma S, Wang S, Sun G. Meta-analysis of saturated fatty acid intake and breast cancer risk. *Medicine*. 2015 Dec;94(52):e2391.
- 24 Xu C, Han FF, Zeng XT, Liu TZ, Li S, Gao ZY. Fat intake is not linked to prostate cancer: a systematic review and dose-response meta-analysis. *PLoS One*. 2015;10(7):e0131747.
- 25 Yao X, Tian Z. Saturated, monounsaturated and polyunsaturated fatty acids intake and risk of pancreatic cancer: evidence from observational studies. *PLoS One*. 2015;10(6):e0130870.
- 26 Arab A, Akbarian SA, Ghiyasvand R, Miraghajani M. The effects of conjugated linoleic acids on breast cancer: a systematic review. *Adv Biomed Res*. 2016;5:115.
- 27 Cao Y, Hou L, Wang W. Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: a meta-analysis of prospective cohort studies. *Int J Cancer*. 2016 Apr 15;138(8):1894–904.
- 28 Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci Rep*. 2016 Jun 16;6:28165.
- 29 Cheng P, Wang J, Shao W. Monounsaturated fatty acid intake and stroke risk: a meta-analysis of prospective cohort studies. *J Stroke Cerebrovasc Dis*. 2016 Jun;25(6):1326–34.
- 30 Cheng P, Wang J, Shao W, Liu M, Zhang H. Can dietary saturated fat be beneficial in prevention of stroke risk? A meta-analysis. *Neurol Sci*. 2016 Jul;37(7):1089–98.
- 31 Gong TT, Li D, Wu QJ, Wang YZ. Cholesterol consumption and risk of endometrial cancer: a systematic review and dose-response meta-analysis of observational studies. *Oncotarget*. 2016 Mar 29;7(13):16996–7008.
- 32 Imamura F, Micha R, Wu JH, de Oliveira Otto MC, Otite FO, Abioye AI, et al. Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: a systematic review and meta-analysis of randomised controlled feeding trials. *PLoS Med*. 2016 Jul;13(7):e1002087.
- 33 Li C, Yang L, Zhang D, Jiang W. Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer. *Nutr Res*. 2016 Jul;36(7):627–35.
- 34 Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr*. 2016 Feb 14;115(3):466–79.
- 35 Mensink R. *Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis*. Geneva: World Health Organization; 2016.
- 36 Morio B, Fardet A, Legrand P, Lecerf JM. Involvement of dietary saturated fats, from all sources or of dairy origin only, in insulin resistance and type 2 diabetes. *Nutr Rev*. 2016 Jan;74(1):33–47.
- 37 Qiu W, Lu H, Qi Y, Wang X. Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. *Oncotarget*. 2016 Jun 14;7(24):37390–406.
- 38 Yang B, Shi MQ, Li ZH, Yang JJ, Li D. Fish, long-chain n-3 PUFA and incidence of elevated blood pressure: a meta-analysis of prospective cohort studies. *Nutrients*. 2016 Jan 21;8(1):58.
- 39 Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, et al. Dietary fat intake and endometrial cancer risk: a dose response meta-analysis. *Medicine*. 2016 Jul;95(27):e4121.
- 40 Zhou Y, Wang T, Zhai S, Li W, Meng Q. Linoleic acid and breast cancer risk: a meta-analysis. *Public Health Nutr*. 2016 Jun;19(8):1457–63.
- 41 Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. *Mayo Clin Proc*. 2017 Jan;92(1):15–29.
- 42 Balk EM, Lichtenstein AH. Omega-3 fatty acids and cardiovascular disease: summary of the 2016 agency of healthcare research and quality evidence review. *Nutrients*. 2017 Aug 11;9(8).
- 43 Chen C, Yang Y, Yu X, Hu S, Shao S. Association between omega-3 fatty acids consumption and the risk of type 2 diabetes: a meta-analysis of cohort studies. *J Diabetes Investig*. 2017 Jul;8(4):480–8.
- 44 Han TJ, Li JS, Luan XT, Wang L, Xu HZ. Dietary fat consumption and non-hodgkin's lymphoma risk: a meta-analysis. *Nutr Cancer*. 2017 Feb–Mar;69(2):221–8.
- 45 Hannon BA, Thompson SV, An R, Teran-Garcia M. Clinical outcomes of dietary replacement of saturated fatty acids with unsaturated fat sources in adults with overweight and obesity: a systematic review and meta-analysis of randomized control trials. *Ann Nutr Metab*. 2017;71(1–2):107–17.
- 46 Harcombe Z, Baker JS, Davies B. Evidence from prospective cohort studies does not support current dietary fat guidelines: a systematic review and meta-analysis. *Br J Sports Med*. 2017 Dec;51(24):1743–9.
- 47 Kolahehdouz Mohammadi R, Bagheri M, Kolahehdouz Mohammadi M, Shidfar F. Ruminant trans-fatty acids and risk of breast cancer: a systematic review and meta-analysis of observational studies. *Minerva Endocrinol*. 2017 Dec;42(4):385–96.
- 48 Li FR, Chen GC, Qin J, Wu X. Dietary Fish and long-chain n-3 polyunsaturated fatty acids intake and risk of atrial fibrillation: a meta-analysis. *Nutrients*. 2017 Aug 29;9(9):955.
- 49 Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. *BMJ*. 2017 Nov 14;359:j4849.
- 50 Su H, Liu R, Chang M, Huang J, Wang X. Dietary linoleic acid intake and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. *Food Funct*. 2017 Sep 20;8(9):3091–103.
- 51 Telle-Hansen VH, Christensen JJ, Ulven SM, Holven KB. Does dietary fat affect inflammatory markers in overweight and obese individuals?: a review of randomized controlled trials from 2010 to 2016. *Genes Nutr*. 2017;12:26.
- 52 Wan Y, Zheng J, Wang F, Li D. Fish, long chain omega-3 polyunsaturated fatty acids consumption, and risk of all-cause mortality: a systematic review and dose-response meta-analysis from 23 independent prospective cohort studies. *Asia Pac J Clin Nutr*. 2017;26(5):939–56.
- 53 Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2018 Nov 27;11: Cd012345.
- 54 Cheng P, Pan J, Xia J, Huang W, Bai S, Zhu X, et al. Dietary cholesterol intake and stroke risk: a meta-analysis. *Oncotarget*. 2018 May 22;9(39):25698–707.
- 55 Kim M, Park K. Dietary fat intake and risk of colorectal cancer: a systematic review and meta-analysis of prospective studies. *Nutrients*. 2018 Dec 12;10(12):1963.
- 56 Lin X, Liu L, Fu Y, Gao J, He Y, Wu Y, et al. Dietary cholesterol intake and risk of lung cancer: a meta-analysis. *Nutrients*. 2018 Feb 8;10(2):185.
- 57 Lu M, Wan Y, Yang B, Huggins CE, Li D. Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials. *Br J Nutr*. 2018 Jan;119(1):96–108.
- 58 Wei J, Hou R, Xi Y, Kowalski A, Wang T, Yu Z, et al. The association and dose-response relationship between dietary intake of alpha-linolenic acid and risk of CHD: a systematic review and meta-analysis of cohort studies. *Br J Nutr*. 2018 Jan;119(1):83–9.

- 59 Anjom-Shoae J, Sadeghi O, Larijani B, Esmaillzadeh A. Dietary intake and serum levels of trans fatty acids and risk of breast cancer: a systematic review and dose-response meta-analysis of prospective studies. *Clin Nutr*. 2020 Mar;39(3):755–64.
- 60 Gjuladin-Hellon T, Davies IG, Penson P, Amiri Baghbadorani R. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. *Nutr Rev*. 2019 Mar 1;77(3):161–80.
- 61 Jovanovski E, de Castro Ruiz Marques A, Li D, Ho HVT, Blanco Mejia S, Sievenpiper JL, et al. Effect of high-carbohydrate or high-monounsaturated fatty acid diets on blood pressure: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev*. 2019 Jan 1;77(1):19–31.
- 62 Ruan L, Cheng SP, Zhu QX. Dietary fat intake and the risk of skin cancer: a systematic review and meta-analysis of observational studies. *Nutr Cancer*. 2020;72(3):398–408.
- 63 Wanders AJ, Blom WAM, Zock PL, Geleijnse JM, Brouwer IA, Alsema M. Plant-derived polyunsaturated fatty acids and markers of glucose metabolism and insulin resistance: a meta-analysis of randomized controlled feeding trials. *BMJ Open Diabetes Res Care*. 2019; 7(1):e000585.
- 64 Zhu Y, Bo Y, Liu Y. Dietary total fat, fatty acids intake, and risk of cardiovascular disease: a dose-response meta-analysis of cohort studies. *Lipids Health Dis*. 2019 Apr 6;18(1):91.
- 65 Kang ZQ, Yang Y, Xiao B. Dietary saturated fat intake and risk of stroke: systematic review and dose-response meta-analysis of prospective cohort studies. *Nutr Metab Cardiovasc Dis*. 2020 Feb 10;30(2):179–89.
- 66 Kim Y, Kim J. Intake or blood levels of n-3 polyunsaturated fatty acids and risk of colorectal cancer: a systematic review and meta-analysis of prospective studies. *Cancer Epidemiol Biomarkers Prev*. 2020 Feb;29(2): 288–99.
- 67 Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019; 393(10170):434–45.
- 68 Schwingshackl L, Knüppel S, Michels N, Schwedhelm C, Hoffmann G, Iqbal K, et al. Intake of 12 food groups and disability-adjusted life years from coronary heart disease, stroke, type 2 diabetes, and colorectal cancer in 16 European countries. *Eur J Epidemiol*. 2019 Aug;34(8):765–75.
- 69 Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ*. 2013;346: e7492.
- 70 Ludwig DS, Hu FB, Tappy L, Brand-Miller J. Dietary carbohydrates: role of quality and quantity in chronic disease. *BMJ*. 2018;361: k2340.
- 71 Schwingshackl L, Schlesinger S, Devleeschauwer B, Hoffmann G, Bechthold A, Schwedhelm C, et al. Generating the evidence for risk reduction: a contribution to the future of food-based dietary guidelines. *Proc Nutr Soc*. 2018;77(4):432–44.
- 72 Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. *N Engl J Med*. 1999 Jun 24; 340(25):1994–8.
- 73 Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2015 Jun 10(6):Cd011737.
- 74 Ricci C, Baumgartner J, Zec M, Kruger HS, Smuts CM. Type of dietary fat intakes in relation to all-cause and cause-specific mortality in US adults: an iso-energetic substitution analysis from the American National Health and Nutrition Examination Survey linked to the US mortality registry. *Br J Nutr*. 2018 Feb; 119(4):456–63.
- 75 Yamagishi K, Iso H, Tsugane S. Saturated fat intake and cardiovascular disease in Japanese population. *J Atheroscler Thromb*. 2015; 22(5):435–9.
- 76 Imamura F, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, et al. Dietary quality among men and women in 187 countries in 1990 and 2010: a systematic assessment. *Lancet Glob Health*. 2015 Mar;3(3):e132–42.
- 77 Linseisen J, Welch AA, Ocké M, Amiano P, Agnoli C, Ferrari P, et al. Dietary fat intake in the European prospective investigation into cancer and Nutrition: results from the 24-h dietary recalls. *Eur J Clin Nutr*. 2009 Nov; 63(Suppl 4):S61–80.
- 78 Schwingshackl L, Zähringer J, Beyerbach J, Nagavci B, Hesecker H, Koletzko B, et al. A scoping review of current guidelines on dietary fat and fat quality. *Ann Nutr Metab*. 2021.
- 79 Astrup A, Bertram HC, Bonjour JP, de Groot LC, de Oliveira Otto MC, Feeney EL, et al. WHO draft guidelines on dietary saturated and trans fatty acids: time for a new approach? *BMJ*. 2019 Jul 3;366:l4137.
- 80 Neelakantan N, Seah JYH, van Dam RM. The effect of coconut oil consumption on cardiovascular risk factors: a systematic review and meta-analysis of clinical trials. *Circulation*. 2020 Mar 10;141(10):803–14.
- 81 Pimpin L, Wu JH, Haskelberg H, Del Gobbo L, Mozaffarian D. Is butter back? A systematic review and meta-analysis of butter consumption and risk of cardiovascular disease, diabetes, and total mortality. *PLoS One*. 2016; 11(6):e0158118.
- 82 Schwingshackl L, Lampousi AM, Portillo MP, Romaguera D, Hoffmann G, Boeing H. Olive oil in the prevention and management of type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies and intervention trials. *Nutr Diabetes*. 2017 Apr 10;7(4): e262.
- 83 Schwingshackl L, Krause M, Schmucker C, Hoffmann G, Rucker G, Meerpohl JJ. Impact of different types of olive oil on cardiovascular risk factors: a systematic review and network meta-analysis. *Nutr Metab Cardiovasc Dis*. 2019 Oct;29(10):1030–9.
- 84 Raeisi-Dehkordi H, Amiri M, Humphries KH, Salehi-Abargouei A. The effect of canola oil on body weight and composition: a systematic review and meta-analysis of randomized controlled clinical trials. *Adv Nutr*. 2019 May 1;10(3):419–32.
- 85 Schwingshackl L, Bogensberger B, Benčić A, Knüppel S, Boeing H, Hoffmann G. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. *J Lipid Res*. 2018 Sep;59(9):1771–82.
- 86 O'Sullivan TA, Hafekost K, Mitrou F, Lawrence D. Food sources of saturated fat and the association with mortality: a meta-analysis. *Am J Public Health*. 2013 Sep;103(9):e31–42.
- 87 Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals. *JAMA Cardiol*. 2018;3(3):225–34.
- 88 Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2020;3(3):CD003177.
- 89 Astrup A, Magkos F, Bier DM, Brenna JT, de Oliveira Otto MC, Hill JO, et al. Saturated fats and health: a reassessment and proposal for food-based recommendations: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020 Aug 18;76(7):844–57.
- 90 Schwingshackl L, Hoffmann G, Lampousi AM, Knüppel S, Iqbal K, Schwedhelm C, et al. Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. *Eur J Epidemiol*. 2017 May;32(5):363–75.
- 91 Schwingshackl L, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, Andriolo V, et al. Food groups and risk of hypertension: a systematic review and dose-response meta-analysis of prospective studies. *Adv Nutr*. 2017 Nov;8(6): 793–803.
- 92 Schwingshackl L, Schwedhelm C, Hoffmann G, Knüppel S, Laure Preterre A, Iqbal K, et al. Food groups and risk of colorectal cancer. *Int J Cancer*. 2018 May 1;142(9):1748–58.
- 93 Bechthold A, Boeing H, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, et al. Food groups and risk of coronary heart disease, stroke and heart failure: a systematic review and dose-response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr*. 2019; 59(7):1071–90.
- 94 Schlesinger S, Neuenschwander M, Schwedhelm C, Hoffmann G, Bechthold A, Boeing H, et al. Food groups and risk of overweight, obesity, and weight gain: a systematic review and dose-response meta-analysis of prospective studies. *Adv Nutr*. 2019 Mar 1;10(2):205–18.

- 95 Morze J, Schwedhelm C, Bencic A, Hoffmann G, Boeing H, Przybylowicz K, et al. Chocolate and risk of chronic disease: a systematic review and dose-response meta-analysis. *Eur J Nutr*. 2020 Feb;59(1):389–97.
- 96 Schwingshackl L, Schünemann HJ, Meerpohl JJ. Improving the trustworthiness of findings from nutrition evidence syntheses: assessing risk of bias and rating the certainty of evidence. *Eur J Nutr*. 2020 Dec 30.
- 97 Werner SS, Binder N, Toews I, Schünemann HJ, Meerpohl JJ, Schwingshackl L. Use of the GRADE approach for rating the certainty of evidence in evidence syntheses published in high impact factor nutrition journals: a methodological survey. *J Clin Epi*. 2021. July;135: 54–69. <https://doi.org/10.1016/j.jclinepi.2021.02.010>.
- 98 Song M, Giovannucci E. Substitution analysis in nutritional epidemiology: proceed with caution. *Eur J Epidemiol*. 2018 Feb 1;33(2): 137–40.
- 99 Schwingshackl L, Schwarzer G, Rucker G, Meerpohl JJ. Perspective: network meta-analysis reaches nutrition research: current status, scientific concepts, and future directions. *Adv Nutr*. 2019 Sep 1;10(5):739–54.
- 100 Song M, Giovannucci E. Substitution analysis in nutritional epidemiology: proceed with caution. *Eur J Epidemiol*. 2018 Feb; 33(2):137–40.